Company Insights

CVAC customer relationships

Explore interactive graphBrowse insights index
CVAC customer relationship map

CureVac (CVAC) — Customer map and what it means for investors

CureVac operates as a clinical-stage mRNA drug developer that monetizes its technology through strategic licensing, supply and royalty arrangements rather than through large-scale internal product sales. The company’s near-term cash generation is driven almost entirely by partnership agreements — large one‑time license payments and ongoing royalties — while R&D and a strategic pivot to oncology determine long‑term value creation. Learn more about how we compile counterparty intelligence at https://nullexposure.com/.

How CureVac makes money right now

CureVac has transitioned from a vaccine developer to a licensing-led commercial model. The company has monetized its COVID‑19 and influenza mRNA programs through outbound licenses and U.S. licensing arrangements that generate both lump‑sum fees and recurring royalties; those inflows dominate reported revenue and produce pronounced quarter-to-quarter volatility. At the same time, CureVac is re‑allocating resources to oncology research after licensing its respiratory vaccine assets to large pharma partners.

Key commercial drivers: large, discrete license payments; royalty streams from partners; strategic re‑focus of internal pipeline to higher‑value oncology programs. Visit https://nullexposure.com/ if you want a deeper dive into counterparty revenue dynamics.

Counterparties that define CureVac’s near-term results

The company’s revenue and strategic posture are concentrated in a handful of large pharma partners. Below are concise, source‑backed summaries for every named relationship found in public filings and press coverage.

GlaxoSmithKline (GSK)

CureVac recognized a very large one‑time licensing payment from GSK in 2024 and recorded sharply lower revenues in 2025 as that non‑recurring item fell out of the comparable period; for the nine months ended September 30, 2025 CureVac reported €43.3 million of revenue from GSK. RTTNews highlighted that Q3 2025 revenues fell 89% to €54.1 million primarily because the €480.4 million license payment tied to GSK closed in July 2024 was not repeated in 2025 (FY2025 reporting). Börse.de/EQS News and InvestingNews corroborate the post‑license revenue profile for the half‑ and nine‑month periods (FY2025).

BioNTech / BioNTech SE

CureVac agreed to grant BioNTech a non‑exclusive U.S. license for mRNA COVID‑19 and influenza products and subsequently became a BioNTech acquisition target; CureVac recorded €11.1 million from BioNTech for the nine months ended September 30, 2025. Pharmaceutical Commerce and InvestingNews reported the U.S. license arrangement and noted that the license expands to a worldwide grant following BioNTech’s acquisition; Akti-enCheck reported that BioNTech completed its takeover, after which CureVac shares were removed from public trading (FY2025–FY2026).

Pfizer

CureVac granted Pfizer a non‑exclusive license in the U.S. to produce, import and sell mRNA COVID‑19 and influenza products under the same U.S. license arrangement that also covered BioNTech; CureVac reported royalty income related to that U.S. license, with €11.1 million recognized in Q3 2025 tied to the agreement. Pharmaceutical Commerce and InvestingNews covered the licensing scope and the royalty recognition (FY2025).

Pfizer / BioNTech (joint U.S. license)

CureVac’s U.S. license to Pfizer and BioNTech specifically covers manufacturing, use, import into the United States and sale of mRNA COVID‑19 and influenza products, with the license to be extended internationally once BioNTech’s acquisition of CureVac closes. Pharmaceutical Commerce and 4investors.de documented the U.S. license terms and the planned worldwide expansion post‑acquisition (FY2025).

CRISPR Therapeutics (CRSP)

CureVac generated small, ongoing revenues with CRISPR Therapeutics — recorded as €1.8 million for the nine months ended September 30, 2025 and €1.6 million for the first half of 2025 — a modest but persistent commercial relationship compared with the larger GSK and BioNTech/Pfizer receipts. Börse.de/EQS News and InvestingNews show CRISPR as a minor revenue contributor in FY2025.

Clinical collaborator mention: GlaxoSmithKline use of CureVac backbone (FY2024)

Clinical trial reporting shows GSK used CureVac’s second‑generation mRNA backbone in its multivalent influenza program, where interim data demonstrated antibody titer boosts across strains and age groups. Vax‑Before‑Travel documented the Phase 2 trial results that underpin the technical fit between GSK’s candidate and CureVac’s mRNA platform (FY2024).

What the relationship map means for investors: operating signals and constraints

Several company‑level operating signals emerge from these counterparty facts.

  • Contracting posture: CureVac’s commercial model is partner‑centric and licensing‑heavy; the firm accepts non‑exclusive licenses and royalties rather than pursuing full commercialization of vaccine programs itself. That posture accelerates near‑term cash realization but transfers commercialization execution risk to large partners.
  • Revenue concentration and volatility: A small number of large counterparties produce the majority of near‑term revenues. The presence of a single large one‑time license (GSK in July 2024) explains acute year‑over‑year swings in reported top line and creates forecasting lumpiness.
  • Criticality to partners vs. company: For partners like GSK, BioNTech and Pfizer, CureVac’s value is concentrated in intellectual‑property access (second‑generation mRNA backbone) rather than in sales channels, making CureVac an IP supplier rather than a scale manufacturer—this reduces operating leverage but preserves upside through royalties.
  • Maturity of commercial relationships: The licensing transactions are mature commercial exits for specific programs (respiratory vaccines), while CureVac’s pivot to oncology signals an early‑stage internal pipeline that will require R&D time and capital to monetize.
  • Consolidation risk and strategic outcome: The BioNTech acquisition closes the loop on one strategic counterparty relationship and converts future CureVac revenue into intra‑group economics, changing the public investment case and competitor dynamics.

These constraints are company‑level inferences derived from the relationship evidence rather than specific contractual excerpts.

Valuation and risk implications for investors

The revenue base is predictable only to the extent royalties and small recurring agreements persist; large upfront license receipts create headline earnings but are not repeatable. The BioNTech acquisition materially changes CureVac’s public equity optionality and reduces the utility of standalone counterparty revenue metrics going forward. Investors evaluating CVAC should treat 2024 licensing inflows as non‑recurring cash events and focus on ongoing royalty streams and the success or monetization of the oncology pipeline for future upside.

If you are modeling partner‑driven cash flows or tracking counterparty risk, our coverage provides structured summaries that connect revenue items to counterparties and contract types — see more at https://nullexposure.com/.

Bottom line: who holds the commercial levers?

Large pharmas (GSK, BioNTech, Pfizer) are the primary commercial levers for CureVac; CRISPR is a small revenue partner. The company’s value realization has been transactional to date (licenses, royalties) and is now transitioning under BioNTech ownership into an integrated asset with strategic re‑orientation toward oncology. For investors, that means shifting the focus from one‑off license receipts to the persistence of royalty income and the execution risk of the nascent oncology program.

For a focused investor brief that maps counterparties to cash flows and contractual cadence, visit https://nullexposure.com/ for our full counterparty intelligence and modeling templates.